Xonvea
It’s time to stop normalising
Nausea and Vomiting of
Pregnancy.
It’s time for relief.
Xonvea® is indicated for treatment of nausea and vomiting of pregnancy (NVP) in pregnant women ≥ 18 years who do not respond to conservative management.1
Xonvea® is an antiemetic. It contains two active ingredients.1
-Doxylamine succinate (antihistamine)
-Pyridoxine hydrochloride (Vitamin B6)
Xonvea® Benefits
Only licensed treatment of NVP in the UK
Xonvea® is specifically licensed in the UK to treat NVP in adult patients 18 years or over.1,2
Prescribing Hierarchy Justification
The MHRA has advised that because of prescribing hierarchy, the use of other medicines that do not have a specific license for NVP over Xonvea, which does, would need to be justified.3
Xonvea® for Persistent NVP
Xonvea® can help to manage the symptoms of NVP if conservative management has failed (vs. placebo at day 15; p=0.006).4*
Improving quality of life with Xonvea®
Xonvea® can help to improve quality of life for women experiencing NVP (vs. placebo at day 15; p=0.005).4†
Tailored Xonvea® Treatment
Xonvea® dose can be tailored according to response. Continued need should be assessed throughout pregnancy.1
Xonvea® Is Generally Well-Tolerated
Xonvea® was generally well-tolerated: the most frequently reported adverse reaction (≥5% and exceeding the rate in placebo) was somnolence.1
*Change from baseline measurement in PUQE score.
†Change from baseline measurement in Global Assessment of Well-being score.
Xonvea® Recommended
Xonvea® is the only licensed treatment of nausea and vomiting of pregnancy (NVP) in the UK.1
The 2024 RCOG Guidelines recommend Xonvea® as a first-line treatment option for NVP.2
Care should be taken when prescribing in pregnancy as medicines can cross the placenta and may affect the fetus. Always refer to the full Summary of Product Characteristics prior to prescribing.
Resources
Download helpful materials about Xonvea®, designed to support you in providing the best care for your patients.
Dosing
Xonvea® has a gradual, step-up dosing regimen.
Understanding Xonvea® Safety and Tolerability
Xonvea® has demonstrated an acceptable tolerability profile.
Cost
£28.50
Abbreviations: NVP, Nausea and vomiting of pregnancy; RCOG, Royal College of Obstetricians and Gynaecologists; PUQE, Pregnancy-Unique Qualification of Emesis
References: 1. XONVEA® Summary of Product Characteristics 2. NICE Antenatal care guidance. 2021 3. NICE XONVEA® Evidence Summary. 2019 4. Koren, G., et al. Am J Obstet Gynecol. 2010. 203 (6) 5. Nelson-Piercy et al; Royal College of Obstetricians and Gynaecologists. The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No. 69). BJOG. 2024. 6.NICE BNF Available at: https://bnf.nice.org.uk/drugs/doxylamine-with-pyridoxine/medicinal-forms/ Accessed November 2025.
